ID   CD4_HUMAN               Reviewed;         458 AA.
AC   P01730; B2R737; D3DUS5; Q4ZGK2; Q5U066; Q9UDE5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   28-JAN-2026, entry version 258.
DE   RecName: Full=T-cell surface glycoprotein CD4;
DE   AltName: Full=T-cell surface antigen T4/Leu-3;
DE   AltName: CD_antigen=CD4;
DE   Flags: Precursor;
GN   Name=CD4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=2990730; DOI=10.1016/s0092-8674(85)80105-7;
RA   Maddon P.J., Littman D.R., Godfrey M., Maddon D.E., Chess L., Axel R.;
RT   "The isolation and nucleotide sequence of a cDNA encoding the T cell
RT   surface protein T4: a new member of the immunoglobulin gene family.";
RL   Cell 42:93-104(1985).
RN   [2]
RP   SEQUENCE REVISION TO 26.
RX   PubMed=3263213; DOI=10.1016/0092-8674(88)90211-5;
RA   Littman D.R., Maddon P.J., Axel R.;
RT   "Corrected CD4 sequence.";
RL   Cell 55:541-541(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8723724; DOI=10.1101/gr.6.4.314;
RA   Ansari-Lari M.A., Muzny D.M., Lu J., Lu F., Lilley C.E., Spanos S.,
RA   Malley T., Gibbs R.A.;
RT   "A gene-rich cluster between the CD4 and triosephosphate isomerase genes at
RT   human chromosome 12p13.";
RL   Genome Res. 6:314-326(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Brain;
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], POLYMORPHISM, VARIANT TRP-265, AND TOPOLOGY.
RX   PubMed=1708753; DOI=10.1016/0198-8859(91)90077-m;
RA   Hodge T.W., Sasso D.R., McDougal J.S.;
RT   "Humans with OKT4-epitope deficiency have a single nucleotide base change
RT   in the CD4 gene, resulting in substitution of TRP240 for ARG240.";
RL   Hum. Immunol. 30:99-104(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-191; SER-227 AND
RP   TRP-265.
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-424.
RC   TISSUE=Blood;
RX   PubMed=1425921; DOI=10.1002/eji.1830221132;
RA   Fomsgaard A., Hirsch V.M., Johnson P.R.;
RT   "Cloning and sequences of primate CD4 molecules: diversity of the cellular
RT   receptor for simian immunodeficiency virus/human immunodeficiency virus.";
RL   Eur. J. Immunol. 22:2973-2981(1992).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=2823150; DOI=10.1038/330256a0;
RA   Doyle C., Strominger J.L.;
RT   "Interaction between CD4 and class II MHC molecules mediates cell
RT   adhesion.";
RL   Nature 330:256-259(1987).
RN   [13]
RP   PHOSPHORYLATION.
RX   PubMed=2512251; DOI=10.1007/bf02421181;
RA   DiSanto J.P., Klein J.S., Flomenberg N.;
RT   "Phosphorylation and down-regulation of CD4 and CD8 in human CTLs and mouse
RT   L cells.";
RL   Immunogenetics 30:494-501(1989).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, DISULFIDE BOND, AND GLYCOSYLATION AT
RP   ASN-296 AND ASN-325.
RX   PubMed=2592374; DOI=10.1016/s0021-9258(19)30077-8;
RA   Carr S.A., Hemling M.E., Folena-Wasserman G., Sweet R.W., Anumula K.,
RA   Barr J.R., Huddleston M.J., Taylor P.;
RT   "Protein and carbohydrate structural analysis of a recombinant soluble CD4
RT   receptor by mass spectrometry.";
RL   J. Biol. Chem. 264:21286-21295(1989).
RN   [15]
RP   PROTEIN SEQUENCE OF 26-40, AND TOPOLOGY.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 250-280, POLYMORPHISM, AND VARIANT TRP-265.
RX   PubMed=1961196; DOI=10.1016/0161-5890(91)90003-3;
RA   Lederman S., DeMartino J.A., Daugherty B.L., Foeldvari I., Yellin M.J.,
RA   Cleary A.M., Berkowitz N., Lowy I., Braunstein N.S., Mark G.E.;
RT   "A single amino acid substitution in a common African allele of the CD4
RT   molecule ablates binding of the monoclonal antibody, OKT4.";
RL   Mol. Immunol. 28:1171-1181(1991).
RN   [17]
RP   PHOSPHORYLATION AT SER-433; SER-440 AND SER-456, AND MUTAGENESIS OF
RP   SER-433.
RX   PubMed=2105883; DOI=10.1002/j.1460-2075.1990.tb08127.x;
RA   Shin J., Doyle C., Yang Z., Kappes D., Strominger J.L.;
RT   "Structural features of the cytoplasmic region of CD4 required for
RT   internalization.";
RL   EMBO J. 9:425-434(1990).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HIV-1 ENVELOPE POLYPROTEIN
RP   GP160 (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION (MICROBIAL
RP   INFECTION).
RX   PubMed=2214026; DOI=10.1128/jvi.64.11.5585-5593.1990;
RA   Crise B., Buonocore L., Rose J.K.;
RT   "CD4 is retained in the endoplasmic reticulum by the human immunodeficiency
RT   virus type 1 glycoprotein precursor.";
RL   J. Virol. 64:5585-5593(1990).
RN   [19]
RP   GLYCOSYLATION AT ASN-296 AND ASN-325.
RX   PubMed=2001369; DOI=10.1021/bi00223a015;
RA   Spellman M.W., Leonard C.K., Basa L.J., Gelineo I., van Halbeek H.;
RT   "Carbohydrate structures of recombinant soluble human CD4 expressed in
RT   Chinese hamster ovary cells.";
RL   Biochemistry 30:2395-2406(1991).
RN   [20]
RP   INTERACTION WITH IL16.
RX   PubMed=1673145;
RA   Cruikshank W.W., Greenstein J.L., Theodore A.C., Center D.M.;
RT   "Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic
RT   signaling in lymphocytes.";
RL   J. Immunol. 146:2928-2934(1991).
RN   [21]
RP   PALMITOYLATION AT CYS-419 AND CYS-422.
RX   PubMed=1618861; DOI=10.1016/s0021-9258(18)42253-3;
RA   Crise B., Rose J.K.;
RT   "Identification of palmitoylation sites on CD4, the human immunodeficiency
RT   virus receptor.";
RL   J. Biol. Chem. 267:13593-13597(1992).
RN   [22]
RP   SUBCELLULAR LOCATION (MICROBIAL INFECTION) AND MUTAGENESIS OF MET-432;
RP   SER-433; 438-LEU-LEU-439 AND SER-440.
RX   PubMed=8124721; DOI=10.1016/0092-8674(94)90360-3;
RA   Aiken C., Konner J., Landau N.R., Lenburg M.E., Trono D.;
RT   "Nef induces CD4 endocytosis: requirement for a critical dileucine motif in
RT   the membrane-proximal CD4 cytoplasmic domain.";
RL   Cell 76:853-864(1994).
RN   [23]
RP   TISSUE SPECIFICITY.
RX   PubMed=8088877; DOI=10.1016/0165-2478(94)90178-3;
RA   Winkel K., Sotzik F., Vremec D., Cameron P.U., Shortman K.;
RT   "CD4 and CD8 expression by human and mouse thymic dendritic cells.";
RL   Immunol. Lett. 40:93-99(1994).
RN   [24]
RP   FUNCTION, INTERACTION WITH MHCII, INTERACTION WITH HIV-1 SURFACE PROTEIN
RP   GP120 (MICROBIAL INFECTION), MUTAGENESIS OF PHE-68 AND ARG-265, AND DOMAIN.
RX   PubMed=7604010; DOI=10.1073/pnas.92.14.6444;
RA   Sakihama T., Smolyar A., Reinherz E.L.;
RT   "Oligomerization of CD4 is required for stable binding to class II major
RT   histocompatibility complex proteins but not for interaction with human
RT   immunodeficiency virus gp120.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6444-6448(1995).
RN   [25]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN HERPESVIRUS 7
RP   SURFACE PROTEINS.
RX   PubMed=7909607; DOI=10.1073/pnas.91.9.3872;
RA   Lusso P., Secchiero P., Crowley R.W., Garzino-Demo A., Berneman Z.N.,
RA   Gallo R.C.;
RT   "CD4 is a critical component of the receptor for human herpesvirus 7:
RT   interference with human immunodeficiency virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:3872-3876(1994).
RN   [26]
RP   INTERACTION WITH SPG21, AND MUTAGENESIS OF 457-PRO-ILE-458.
RX   PubMed=11113139; DOI=10.1074/jbc.m009270200;
RA   Zeitlmann L., Sirim P., Kremmer E., Kolanus W.;
RT   "Cloning of ACP33 as a novel intracellular ligand of CD4.";
RL   J. Biol. Chem. 276:9123-9132(2001).
RN   [27]
RP   FUNCTION (MICROBIAL INFECTION), SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=12089508; DOI=10.1038/ni815;
RA   Matthias L.J., Yam P.T., Jiang X.M., Vandegraaff N., Li P., Poumbourios P.,
RA   Donoghue N., Hogg P.J.;
RT   "Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1.";
RL   Nat. Immunol. 3:727-732(2002).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH LCK, AND TOPOLOGY.
RX   PubMed=12517957; DOI=10.4049/jimmunol.170.2.913;
RA   Fragoso R., Ren D., Zhang X., Su M.W., Burakoff S.J., Jin Y.J.;
RT   "Lipid raft distribution of CD4 depends on its palmitoylation and
RT   association with Lck, and evidence for CD4-induced lipid raft aggregation
RT   as an additional mechanism to enhance CD3 signaling.";
RL   J. Immunol. 170:913-921(2003).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 SURFACE PROTEIN
RP   GP120 (MICROBIAL INFECTION).
RX   PubMed=16331979; DOI=10.1021/bi051120s;
RA   Sharma D., Balamurali M.M., Chakraborty K., Kumaran S., Jeganathan S.,
RA   Rashid U., Ingallinella P., Varadarajan R.;
RT   "Protein minimization of the gp120 binding region of human CD4.";
RL   Biochemistry 44:16192-16202(2005).
RN   [30]
RP   INTERACTION WITH LCK.
RX   PubMed=16888650; DOI=10.1038/sj.embor.7400775;
RA   Loewenberg M., Verhaar A.P., Bilderbeek J., Marle J.V., Buttgereit F.,
RA   Peppelenbosch M.P., van Deventer S.J., Hommes D.W.;
RT   "Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated
RT   protein complex containing LCK and FYN.";
RL   EMBO Rep. 7:1023-1029(2006).
RN   [31]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16951326; DOI=10.4049/jimmunol.177.6.3669;
RA   Bernstein H.B., Plasterer M.C., Schiff S.E., Kitchen C.M., Kitchen S.,
RA   Zack J.A.;
RT   "CD4 expression on activated NK cells: ligation of CD4 induces cytokine
RT   expression and cell migration.";
RL   J. Immunol. 177:3669-3676(2006).
RN   [32]
RP   FUNCTION (MICROBIAL INFECTION), AND REVIEW.
RX   PubMed=17346169; DOI=10.2174/156652407780059177;
RA   Lindwasser O.W., Chaudhuri R., Bonifacino J.S.;
RT   "Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate
RT   immunodeficiency viruses.";
RL   Curr. Mol. Med. 7:171-184(2007).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-296.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=24696433; DOI=10.1128/cmr.00097-13;
RA   Tubo N.J., Jenkins M.K.;
RT   "CD4+ T Cells: guardians of the phagosome.";
RL   Clin. Microbiol. Rev. 27:200-213(2014).
RN   [35]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=24942581; DOI=10.1128/jvi.00616-14;
RA   Zhen A., Krutzik S.R., Levin B.R., Kasparian S., Zack J.A., Kitchen S.G.;
RT   "CD4 ligation on human blood monocytes triggers macrophage differentiation
RT   and enhances HIV infection.";
RL   J. Virol. 88:9934-9946(2014).
RN   [36]
RP   INTERACTION WITH MHCII.
RX   PubMed=27114505; DOI=10.1073/pnas.1513918113;
RA   Joensson P., Southcombe J.H., Santos A.M., Huo J., Fernandes R.A.,
RA   McColl J., Lever M., Evans E.J., Hudson A., Chang V.T., Hanke T.,
RA   Godkin A., Dunne P.D., Horrocks M.H., Palayret M., Screaton G.R.,
RA   Petersen J., Rossjohn J., Fugger L., Dushek O., Xu X.N., Davis S.J.,
RA   Klenerman D.;
RT   "Remarkably low affinity of CD4/peptide-major histocompatibility complex
RT   class II protein interactions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:5682-5687(2016).
RN   [37]
RP   INTERACTION WITH MOSQUITO LONG FORM SALIVARY PROTEIN D7L2;
RP   NEUTROPHIL-STIMULATING FACTOR 1 AND VENOM ALLERGEN-1.
RX   PubMed=36070318; DOI=10.1371/journal.pntd.0010743;
RA   Gavor E., Choong Y.K., Liu Y., Pompon J., Ooi E.E., Mok Y.K., Liu H.,
RA   Kini R.M., Sivaraman J.;
RT   "Identification of Aedes aegypti salivary gland proteins interacting with
RT   human immune receptor proteins.";
RL   PLoS Negl. Trop. Dis. 16:e0010743-e0010743(2022).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-208.
RX   PubMed=1701030; DOI=10.1038/348411a0;
RA   Wang J., Yan Y., Garrett T.P., Liu J., Rodgers D.W., Garlick R.L.,
RA   Tarr G.E., Husain Y., Reinherz E.L., Harrison S.C.;
RT   "Atomic structure of a fragment of human CD4 containing two immunoglobulin-
RT   like domains.";
RL   Nature 348:411-418(1990).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-208.
RX   PubMed=2247146; DOI=10.1038/348419a0;
RA   Ryu S.-E., Kwong P.D., Truneh A., Porter T.G., Arthos J., Rosenberg M.,
RA   Dai X., Xuong N.-H., Axel R., Sweet R.W., Hendrickson W.A.;
RT   "Crystal structure of an HIV-binding recombinant fragment of human CD4.";
RL   Nature 348:419-426(1990).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 26-388, HOMODIMERIZATION,
RP   INTERACTION WITH CD81, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-445 AND
RP   CYS-447.
RX   PubMed=9168119; DOI=10.1038/387527a0;
RA   Wu H., Kwong P.D., Hendrickson W.A.;
RT   "Dimeric association and segmental variability in the structure of human
RT   CD4.";
RL   Nature 387:527-530(1997).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 26-208 IN COMPLEX WITH HIV SURFACE
RP   PROTEIN GP120 (MICROBIAL INFECTION), AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=9641677; DOI=10.1038/31405;
RA   Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J.,
RA   Hendrickson W.A.;
RT   "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4
RT   receptor and a neutralizing human antibody.";
RL   Nature 393:648-659(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.82 ANGSTROMS) OF 428-450 IN COMPLEX WITH
RP   PTK2/FAK1, AND INTERACTION WITH PTK2/FAK1.
RX   PubMed=18078954; DOI=10.1016/j.jmb.2007.11.040;
RA   Garron M.L., Arthos J., Guichou J.F., McNally J., Cicala C., Arold S.T.;
RT   "Structural basis for the interaction between focal adhesion kinase and
RT   CD4.";
RL   J. Mol. Biol. 375:1320-1328(2008).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 26-203, INTERACTION WITH MHCII,
RP   MUTAGENESIS OF GLN-65; THR-70; SER-85 AND ASP-88, AND DOMAIN.
RX   PubMed=21900604; DOI=10.1073/pnas.1109438108;
RA   Wang X.X., Li Y., Yin Y., Mo M., Wang Q., Gao W., Wang L., Mariuzza R.A.;
RT   "Affinity maturation of human CD4 by yeast surface display and crystal
RT   structure of a CD4-HLA-DR1 complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:15960-15965(2011).
RN   [44]
RP   INVOLVEMENT IN IMD79.
RX   PubMed=31781092; DOI=10.3389/fimmu.2019.02502;
RA   Fernandes R.A., Perez-Andres M., Blanco E., Jara-Acevedo M., Criado I.,
RA   Almeida J., Botafogo V., Coutinho I., Paiva A., van Dongen J.J.M.,
RA   Orfao A., Faria E.;
RT   "Complete Multilineage CD4 Expression Defect Associated With Warts Due to
RT   an Inherited Homozygous CD4 Gene Mutation.";
RL   Front. Immunol. 10:2502-2502(2019).
RN   [45]
RP   INVOLVEMENT IN IMD79.
RX   PubMed=33471124; DOI=10.1093/infdis/jiab025;
RA   Lisco A., Ye P., Wong C.S., Pei L., Hsu A.P., Mace E.M., Orange J.S.,
RA   Lage S.L., Ward A.J., Migueles S.A., Connors M., Anderson M.V.,
RA   Buckner C.M., Moir S., Rupert A., Dulau-Florea A., Ogbogu P.,
RA   Timberlake D., Notarangelo L.D., Pittaluga S., Abraham R.S., Sereti I.;
RT   "Lost in Translation: Lack of CD4 Expression due to a Novel Genetic
RT   Defect.";
RL   J. Infect. Dis. 223:645-654(2021).
CC   -!- FUNCTION: Integral membrane glycoprotein that plays an essential role
CC       in the immune response and serves multiple functions in responses
CC       against both external and internal offenses. In T-cells, functions
CC       primarily as a coreceptor for MHC class II molecule:peptide complex.
CC       The antigens presented by class II peptides are derived from
CC       extracellular proteins while class I peptides are derived from
CC       cytosolic proteins. Interacts simultaneously with the T-cell receptor
CC       (TCR) and the MHC class II presented by antigen presenting cells
CC       (APCs). In turn, recruits the Src kinase LCK to the vicinity of the
CC       TCR-CD3 complex. LCK then initiates different intracellular signaling
CC       pathways by phosphorylating various substrates ultimately leading to
CC       lymphokine production, motility, adhesion and activation of T-helper
CC       cells. In other cells such as macrophages or NK cells, plays a role in
CC       differentiation/activation, cytokine expression and cell migration in a
CC       TCR/LCK-independent pathway. Participates in the development of T-
CC       helper cells in the thymus and triggers the differentiation of
CC       monocytes into functional mature macrophages.
CC       {ECO:0000269|PubMed:12517957, ECO:0000269|PubMed:16951326,
CC       ECO:0000269|PubMed:24942581, ECO:0000269|PubMed:2823150,
CC       ECO:0000269|PubMed:7604010}.
CC   -!- FUNCTION: (Microbial infection) Primary receptor for human
CC       immunodeficiency virus-1 (HIV-1) (PubMed:12089508, PubMed:16331979,
CC       PubMed:2214026, PubMed:9641677). Down-regulated by HIV-1 Vpu
CC       (PubMed:17346169). Acts as a receptor for Human Herpes virus 7/HHV-7
CC       (PubMed:7909607). {ECO:0000269|PubMed:12089508,
CC       ECO:0000269|PubMed:16331979, ECO:0000269|PubMed:17346169,
CC       ECO:0000269|PubMed:2214026, ECO:0000269|PubMed:7909607,
CC       ECO:0000269|PubMed:9641677}.
CC   -!- SUBUNIT: Forms disulfide-linked homodimers at the cell surface.
CC       Interacts with LCK (PubMed:16888650). Interacts with PTK2/FAK1
CC       (PubMed:18078954). Binds to P4HB/PDI. Interacts with IL16; this
CC       interaction induces a CD4-dependent signaling in lymphocytes
CC       (PubMed:1673145). Interacts (via Ig-like V-type domain) with MHCII
CC       alpha chain (via alpha-2 domain) and beta chain (via beta-2 domain);
CC       this interaction increases the affinity of TCR for peptide-MHCII. CD4
CC       oligomerization via Ig-like C2-type 2 and 3 domains appears to be
CC       required for stable binding to MHCII and adhesion between T cells and
CC       APCs (PubMed:21900604, PubMed:27114505, PubMed:7604010). Interacts with
CC       Aedes aegypti long form salivary protein D7L2 (PubMed:36070318).
CC       Interacts with Aedes aegypti neutrophil-stimulating factor 1
CC       (PubMed:36070318). Interacts with Aedes aegypti venom allergen-1
CC       (PubMed:36070318). {ECO:0000269|PubMed:11113139,
CC       ECO:0000269|PubMed:12089508, ECO:0000269|PubMed:1673145,
CC       ECO:0000269|PubMed:16888650, ECO:0000269|PubMed:18078954,
CC       ECO:0000269|PubMed:21900604, ECO:0000269|PubMed:27114505,
CC       ECO:0000269|PubMed:36070318, ECO:0000269|PubMed:7604010}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Envelope
CC       polyprotein gp160 and protein Vpu (PubMed:16331979, PubMed:2214026,
CC       PubMed:7604010, PubMed:9641677). {ECO:0000269|PubMed:16331979,
CC       ECO:0000269|PubMed:2214026, ECO:0000269|PubMed:7604010,
CC       ECO:0000269|PubMed:9641677}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Human Herpes virus 7
CC       surface proteins. {ECO:0000269|PubMed:7909607}.
CC   -!- INTERACTION:
CC       P01730; P51681: CCR5; NbExp=3; IntAct=EBI-353826, EBI-489374;
CC       P01730; P01730: CD4; NbExp=2; IntAct=EBI-353826, EBI-353826;
CC       P01730; P13473-2: LAMP2; NbExp=3; IntAct=EBI-353826, EBI-21591415;
CC       P01730; P06239: LCK; NbExp=3; IntAct=EBI-353826, EBI-1348;
CC       P01730; P04150: NR3C1; NbExp=2; IntAct=EBI-353826, EBI-493507;
CC       P01730; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-353826, EBI-2623095;
CC       P01730; P04578: env; Xeno; NbExp=2; IntAct=EBI-353826, EBI-6163496;
CC       P01730; PRO_0000038427 [P04578]: env; Xeno; NbExp=3; IntAct=EBI-353826, EBI-6179761;
CC       P01730; Q1PHM6: env; Xeno; NbExp=2; IntAct=EBI-353826, EBI-15845606;
CC       P01730; Q2N0S6: env; Xeno; NbExp=3; IntAct=EBI-353826, EBI-16080048;
CC       P01730; P03407: nef; Xeno; NbExp=2; IntAct=EBI-353826, EBI-7355020;
CC       P01730; P05919: vpu; Xeno; NbExp=3; IntAct=EBI-353826, EBI-6164626;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12089508,
CC       ECO:0000269|PubMed:12517957, ECO:0000269|PubMed:2823150,
CC       ECO:0000269|PubMed:2990730}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:12517957, ECO:0000269|PubMed:15340161,
CC       ECO:0000269|PubMed:1708753}. Note=Localizes to lipid rafts
CC       (PubMed:12517957, PubMed:9168119). Removed from plasma membrane by HIV-
CC       1 Nef protein that increases clathrin-dependent endocytosis of this
CC       antigen to target it to lysosomal degradation. Cell surface expression
CC       is also down-modulated by HIV-1 Envelope polyprotein gp160 that
CC       interacts with, and sequesters CD4 in the endoplasmic reticulum.
CC   -!- TISSUE SPECIFICITY: Highly expressed in T-helper cells. The presence of
CC       CD4 is a hallmark of T-helper cells which are specialized in the
CC       activation and growth of cytotoxic T-cells, regulation of B cells, or
CC       activation of phagocytes. CD4 is also present in other immune cells
CC       such as macrophages, dendritic cells or NK cells.
CC       {ECO:0000269|PubMed:16951326, ECO:0000269|PubMed:24942581,
CC       ECO:0000269|PubMed:8088877}.
CC   -!- DOMAIN: The Ig-like V-type domain mediates the interaction with MHCII.
CC       {ECO:0000269|PubMed:21900604, ECO:0000269|PubMed:7604010}.
CC   -!- PTM: Palmitoylation and association with LCK contribute to the
CC       enrichment of CD4 in lipid rafts. {ECO:0000269|PubMed:1618861}.
CC   -!- PTM: Phosphorylated by PKC; phosphorylation at Ser-433 plays an
CC       important role for CD4 internalization. {ECO:0000269|PubMed:2105883,
CC       ECO:0000269|PubMed:2512251}.
CC   -!- POLYMORPHISM: The OKT monoclonal antibodies are widely used for the
CC       analysis of human peripheral blood T-lymphocytes. OKT4 reacts with T-
CC       helper/inducer lymphocytes. The OKT4 epitope of the CD4 cell-surface
CC       protein is polymorphic in white, black, and Japanese populations. The
CC       variable phenotypic expression is due a CD4 polymorphism. OKT4 positive
CC       individuals carry Arg-265 and OKT4 negative individuals carry Trp-265
CC       [MIM:613949]. {ECO:0000269|PubMed:1708753, ECO:0000269|PubMed:1961196}.
CC   -!- DISEASE: Immunodeficiency 79 (IMD79) [MIM:619238]: An autosomal
CC       recessive disorder characterized by childhood onset of recurrent and
CC       recalcitrant skin warts due to uncontrolled viral infection with human
CC       papillomavirus (HPV). Some patients may also have recurrent respiratory
CC       infections. Laboratory studies show a complete absence of CD4+ T cells.
CC       {ECO:0000269|PubMed:31781092, ECO:0000269|PubMed:33471124}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD4 entry;
CC       URL="https://en.wikipedia.org/wiki/CD4";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M12807; AAA35572.1; -; mRNA.
DR   EMBL; U47924; AAB51309.1; -; Genomic_DNA.
DR   EMBL; M35160; AAA16069.1; -; mRNA.
DR   EMBL; BT019791; AAV38594.1; -; mRNA.
DR   EMBL; BT019811; AAV38614.1; -; mRNA.
DR   EMBL; DQ012936; AAY22175.1; -; Genomic_DNA.
DR   EMBL; AK312828; BAG35684.1; -; mRNA.
DR   EMBL; CH471116; EAW88738.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88739.1; -; Genomic_DNA.
DR   EMBL; BC025782; AAH25782.1; -; mRNA.
DR   CCDS; CCDS8562.1; -.
DR   PIR; A90872; RWHUT4.
DR   RefSeq; NP_000607.1; NM_000616.5.
DR   RefSeq; NP_001369636.1; NM_001382707.1.
DR   PDB; 1CDH; X-ray; 2.30 A; A=26-203.
DR   PDB; 1CDI; X-ray; 2.90 A; A=26-203.
DR   PDB; 1CDJ; X-ray; 2.50 A; A=26-203.
DR   PDB; 1CDU; X-ray; 2.70 A; A=26-203.
DR   PDB; 1CDY; X-ray; 2.00 A; A=26-203.
DR   PDB; 1G9M; X-ray; 2.20 A; C=26-208.
DR   PDB; 1G9N; X-ray; 2.90 A; C=26-208.
DR   PDB; 1GC1; X-ray; 2.50 A; C=26-206.
DR   PDB; 1JL4; X-ray; 4.30 A; D=26-203.
DR   PDB; 1Q68; NMR; -; A=421-458.
DR   PDB; 1RZJ; X-ray; 2.20 A; C=26-208.
DR   PDB; 1RZK; X-ray; 2.90 A; C=26-208.
DR   PDB; 1WBR; NMR; -; A=428-444.
DR   PDB; 1WIO; X-ray; 3.90 A; A/B=26-388.
DR   PDB; 1WIP; X-ray; 4.00 A; A/B=26-388.
DR   PDB; 1WIQ; X-ray; 5.00 A; A/B=26-388.
DR   PDB; 2B4C; X-ray; 3.30 A; C=26-206.
DR   PDB; 2JKR; X-ray; 2.98 A; P/Q=431-441.
DR   PDB; 2JKT; X-ray; 3.40 A; P/Q=435-441.
DR   PDB; 2KLU; NMR; -; A=397-458.
DR   PDB; 2NXY; X-ray; 2.00 A; B=26-208.
DR   PDB; 2NXZ; X-ray; 2.04 A; B=26-208.
DR   PDB; 2NY0; X-ray; 2.20 A; B=26-208.
DR   PDB; 2NY1; X-ray; 1.99 A; B=26-208.
DR   PDB; 2NY2; X-ray; 2.00 A; B=26-208.
DR   PDB; 2NY3; X-ray; 2.00 A; B=26-208.
DR   PDB; 2NY4; X-ray; 2.00 A; B=26-208.
DR   PDB; 2NY5; X-ray; 2.50 A; C=26-208.
DR   PDB; 2NY6; X-ray; 2.80 A; B=26-208.
DR   PDB; 2QAD; X-ray; 3.30 A; B/F=26-206.
DR   PDB; 3B71; X-ray; 2.82 A; D/E/F=428-450.
DR   PDB; 3CD4; X-ray; 2.20 A; A=26-207.
DR   PDB; 3J70; EM; -; C/O/T=26-208.
DR   PDB; 3JCB; EM; -; D=26-200.
DR   PDB; 3JCC; EM; -; D=26-200.
DR   PDB; 3JWD; X-ray; 2.61 A; C/D=26-208.
DR   PDB; 3JWO; X-ray; 3.51 A; C=26-208.
DR   PDB; 3LQA; X-ray; 3.40 A; C=26-207.
DR   PDB; 3O2D; X-ray; 2.19 A; A=26-207.
DR   PDB; 3S4S; X-ray; 2.40 A; G/H=26-203.
DR   PDB; 3S5L; X-ray; 2.10 A; G/H=26-203.
DR   PDB; 3T0E; X-ray; 4.00 A; E=26-388.
DR   PDB; 4H8W; X-ray; 1.85 A; C=26-208.
DR   PDB; 4JM2; X-ray; 3.10 A; F=26-208.
DR   PDB; 4P9H; X-ray; 3.00 A; C=26-207.
DR   PDB; 4Q6I; X-ray; 3.65 A; C/I/J/K=1-208.
DR   PDB; 4R2G; X-ray; 3.28 A; B/F/H/L=26-208.
DR   PDB; 4R4H; X-ray; 4.28 A; B=26-203.
DR   PDB; 4RQS; X-ray; 4.49 A; B=26-208.
DR   PDB; 5A7X; EM; 17.00 A; B/F/J=26-206.
DR   PDB; 5A8H; EM; 23.00 A; B/H/N=26-208.
DR   PDB; 5CAY; X-ray; 3.00 A; B=26-208.
DR   PDB; 5THR; EM; 8.90 A; G/H/I=26-207.
DR   PDB; 5U1F; EM; 6.80 A; M=26-388.
DR   PDB; 5VN3; EM; 3.70 A; C/E/F=26-208.
DR   PDB; 6CM3; EM; 3.54 A; G/H/I=26-207.
DR   PDB; 6EDU; EM; 4.06 A; G/H/I=26-208.
DR   PDB; 6L1Y; X-ray; 2.47 A; C=26-202.
DR   PDB; 6MEO; EM; 3.90 A; A=26-201.
DR   PDB; 6MET; EM; 4.50 A; A=26-388.
DR   PDB; 6OPN; EM; 3.50 A; C/F/I=25-203.
DR   PDB; 6OPO; EM; 3.50 A; C/G/N=25-203.
DR   PDB; 6OPP; EM; 3.70 A; C/F/M=25-203.
DR   PDB; 6OPQ; EM; 3.80 A; C/I/J=25-203.
DR   PDB; 6QH6; X-ray; 5.00 A; Q=431-440.
DR   PDB; 6QH7; X-ray; 3.40 A; Q=431-440.
DR   PDB; 6U0L; EM; 3.30 A; D/E/F=26-207.
DR   PDB; 6U0N; EM; 3.50 A; D/E/F=26-207.
DR   PDB; 6URI; X-ray; 3.00 A; D=419-444.
DR   PDB; 6X5B; EM; 3.60 A; C/G/N=25-203.
DR   PDB; 6X5C; EM; 4.04 A; C/I/J=25-203.
DR   PDB; 7T0O; EM; 8.70 A; H/L/M=26-389.
DR   PDB; 7T0R; X-ray; 3.65 A; A/D=26-389.
DR   PDB; 7TXD; EM; 3.87 A; G/H/I=26-208.
DR   PDB; 8D5C; EM; 3.90 A; D/E/F=26-208.
DR   PDB; 8FYI; EM; 3.40 A; Z=26-396.
DR   PDB; 8FYJ; EM; 4.00 A; Y/Z=26-396.
DR   PDB; 8W90; X-ray; 1.81 A; B/D/F=26-203.
DR   PDB; 8Z7N; EM; 3.58 A; C/F/I=1-392.
DR   PDB; 9D8Y; EM; 4.06 A; M/N/O=26-121.
DR   PDB; 9D90; EM; 3.91 A; M/N/O=26-206.
DR   PDB; 9D98; EM; 4.19 A; M/N/O=26-206.
DR   PDBsum; 1CDH; -.
DR   PDBsum; 1CDI; -.
DR   PDBsum; 1CDJ; -.
DR   PDBsum; 1CDU; -.
DR   PDBsum; 1CDY; -.
DR   PDBsum; 1G9M; -.
DR   PDBsum; 1G9N; -.
DR   PDBsum; 1GC1; -.
DR   PDBsum; 1JL4; -.
DR   PDBsum; 1Q68; -.
DR   PDBsum; 1RZJ; -.
DR   PDBsum; 1RZK; -.
DR   PDBsum; 1WBR; -.
DR   PDBsum; 1WIO; -.
DR   PDBsum; 1WIP; -.
DR   PDBsum; 1WIQ; -.
DR   PDBsum; 2B4C; -.
DR   PDBsum; 2JKR; -.
DR   PDBsum; 2JKT; -.
DR   PDBsum; 2KLU; -.
DR   PDBsum; 2NXY; -.
DR   PDBsum; 2NXZ; -.
DR   PDBsum; 2NY0; -.
DR   PDBsum; 2NY1; -.
DR   PDBsum; 2NY2; -.
DR   PDBsum; 2NY3; -.
DR   PDBsum; 2NY4; -.
DR   PDBsum; 2NY5; -.
DR   PDBsum; 2NY6; -.
DR   PDBsum; 2QAD; -.
DR   PDBsum; 3B71; -.
DR   PDBsum; 3CD4; -.
DR   PDBsum; 3J70; -.
DR   PDBsum; 3JCB; -.
DR   PDBsum; 3JCC; -.
DR   PDBsum; 3JWD; -.
DR   PDBsum; 3JWO; -.
DR   PDBsum; 3LQA; -.
DR   PDBsum; 3O2D; -.
DR   PDBsum; 3S4S; -.
DR   PDBsum; 3S5L; -.
DR   PDBsum; 3T0E; -.
DR   PDBsum; 4H8W; -.
DR   PDBsum; 4JM2; -.
DR   PDBsum; 4P9H; -.
DR   PDBsum; 4Q6I; -.
DR   PDBsum; 4R2G; -.
DR   PDBsum; 4R4H; -.
DR   PDBsum; 4RQS; -.
DR   PDBsum; 5A7X; -.
DR   PDBsum; 5A8H; -.
DR   PDBsum; 5CAY; -.
DR   PDBsum; 5THR; -.
DR   PDBsum; 5U1F; -.
DR   PDBsum; 5VN3; -.
DR   PDBsum; 6CM3; -.
DR   PDBsum; 6EDU; -.
DR   PDBsum; 6L1Y; -.
DR   PDBsum; 6MEO; -.
DR   PDBsum; 6MET; -.
DR   PDBsum; 6OPN; -.
DR   PDBsum; 6OPO; -.
DR   PDBsum; 6OPP; -.
DR   PDBsum; 6OPQ; -.
DR   PDBsum; 6QH6; -.
DR   PDBsum; 6QH7; -.
DR   PDBsum; 6U0L; -.
DR   PDBsum; 6U0N; -.
DR   PDBsum; 6URI; -.
DR   PDBsum; 6X5B; -.
DR   PDBsum; 6X5C; -.
DR   PDBsum; 7T0O; -.
DR   PDBsum; 7T0R; -.
DR   PDBsum; 7TXD; -.
DR   PDBsum; 8D5C; -.
DR   PDBsum; 8FYI; -.
DR   PDBsum; 8FYJ; -.
DR   PDBsum; 8W90; -.
DR   PDBsum; 8Z7N; -.
DR   PDBsum; 9D8Y; -.
DR   PDBsum; 9D90; -.
DR   PDBsum; 9D98; -.
DR   AlphaFoldDB; P01730; -.
DR   EMDB; EMD-20150; -.
DR   EMDB; EMD-20151; -.
DR   EMDB; EMD-20152; -.
DR   EMDB; EMD-20153; -.
DR   EMDB; EMD-20605; -.
DR   EMDB; EMD-20608; -.
DR   EMDB; EMD-22048; -.
DR   EMDB; EMD-22049; -.
DR   EMDB; EMD-25581; -.
DR   EMDB; EMD-26157; -.
DR   EMDB; EMD-27208; -.
DR   EMDB; EMD-29579; -.
DR   EMDB; EMD-29580; -.
DR   EMDB; EMD-39820; -.
DR   EMDB; EMD-46653; -.
DR   EMDB; EMD-46655; -.
DR   EMDB; EMD-46670; -.
DR   EMDB; EMD-6542; -.
DR   EMDB; EMD-6543; -.
DR   EMDB; EMD-7516; -.
DR   EMDB; EMD-8407; -.
DR   EMDB; EMD-8713; -.
DR   EMDB; EMD-8715; -.
DR   EMDB; EMD-8729; -.
DR   EMDB; EMD-8730; -.
DR   EMDB; EMD-9038; -.
DR   EMDB; EMD-9108; -.
DR   EMDB; EMD-9109; -.
DR   SMR; P01730; -.
DR   BioGRID; 107358; 100.
DR   ComplexPortal; CPX-10161; Interleukin-16 receptor-ligand complex.
DR   CORUM; P01730; -.
DR   DIP; DIP-617N; -.
DR   ELM; P01730; -.
DR   FunCoup; P01730; 703.
DR   IntAct; P01730; 43.
DR   MINT; P01730; -.
DR   STRING; 9606.ENSP00000011653; -.
DR   BindingDB; P01730; -.
DR   ChEMBL; CHEMBL2754; -.
DR   DrugBank; DB00098; Antithymocyte immunoglobulin (rabbit).
DR   DrugBank; DB06241; Clenoliximab.
DR   DrugBank; DB12698; Ibalizumab.
DR   DrugCentral; P01730; -.
DR   TCDB; 8.A.23.2.1; the basigin (basigin) family.
DR   GlyConnect; 587; 31 N-Linked glycans (2 sites).
DR   GlyCosmos; P01730; 2 sites, 54 glycans.
DR   GlyGen; P01730; 7 sites, 58 N-linked glycans (3 sites).
DR   iPTMnet; P01730; -.
DR   PhosphoSitePlus; P01730; -.
DR   SwissPalm; P01730; -.
DR   BioMuta; CD4; -.
DR   DMDM; 116013; -.
DR   jPOST; P01730; -.
DR   MassIVE; P01730; -.
DR   PaxDb; 9606-ENSP00000011653; -.
DR   PeptideAtlas; P01730; -.
DR   ProteomicsDB; 51451; -.
DR   ABCD; P01730; 57 sequenced antibodies.
DR   Antibodypedia; 1341; 7179 antibodies from 63 providers.
DR   CPTC; P01730; 4 antibodies.
DR   DNASU; 920; -.
DR   Ensembl; ENST00000011653.9; ENSP00000011653.4; ENSG00000010610.11.
DR   GeneID; 920; -.
DR   KEGG; hsa:920; -.
DR   MANE-Select; ENST00000011653.9; ENSP00000011653.4; NM_000616.5; NP_000607.1.
DR   UCSC; uc001qqv.3; human.
DR   AGR; HGNC:1678; -.
DR   ClinPGx; PA26220; -.
DR   CTD; 920; -.
DR   DisGeNET; 920; -.
DR   GeneCards; CD4; -.
DR   HGNC; HGNC:1678; CD4.
DR   HPA; ENSG00000010610; Tissue enhanced (liver, lymphoid tissue, parathyroid gland).
DR   MalaCards; CD4; -.
DR   MIM; 186940; gene.
DR   MIM; 613949; phenotype.
DR   MIM; 619238; phenotype.
DR   OpenTargets; ENSG00000010610; -.
DR   VEuPathDB; HostDB:ENSG00000010610; -.
DR   eggNOG; ENOG502S0W5; Eukaryota.
DR   GeneTree; ENSGT00390000001745; -.
DR   HOGENOM; CLU_047414_0_0_1; -.
DR   InParanoid; P01730; -.
DR   OMA; KTCQCSH; -.
DR   OrthoDB; 8657369at2759; -.
DR   PAN-GO; P01730; 7 GO annotations based on evolutionary models.
DR   PhylomeDB; P01730; -.
DR   PathwayCommons; P01730; -.
DR   Reactome; R-HSA-1462054; Alpha-defensins.
DR   Reactome; R-HSA-167590; Nef Mediated CD4 Down-regulation.
DR   Reactome; R-HSA-173107; Binding and entry of HIV virion.
DR   Reactome; R-HSA-180534; Vpu mediated degradation of CD4.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-389948; Co-inhibition by PD-1.
DR   Reactome; R-HSA-449836; Other interleukin signaling.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; P01730; -.
DR   SIGNOR; P01730; -.
DR   Agora; ENSG00000010610; -.
DR   BioGRID-ORCS; 920; 22 hits in 1160 CRISPR screens.
DR   ChiTaRS; CD4; human.
DR   EvolutionaryTrace; P01730; -.
DR   GeneWiki; CD4; -.
DR   GenomeRNAi; 920; -.
DR   Pharos; P01730; Tclin.
DR   PRO; PR:P01730; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P01730; protein.
DR   Bgee; ENSG00000010610; Expressed in granulocyte and 167 other cell types or tissues.
DR   ExpressionAtlas; P01730; baseline and differential.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042101; C:T cell receptor complex; NAS:UniProtKB.
DR   GO; GO:0015026; F:coreceptor activity; IDA:UniProt.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019865; F:immunoglobulin binding; IEA:Ensembl.
DR   GO; GO:0042011; F:interleukin-16 binding; IPI:CAFA.
DR   GO; GO:0042012; F:interleukin-16 receptor activity; IDA:CAFA.
DR   GO; GO:0008289; F:lipid binding; EXP:DisProt.
DR   GO; GO:0042289; F:MHC class II protein binding; IDA:UniProtKB.
DR   GO; GO:0023026; F:MHC class II protein complex binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IDA:UniProt.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0019722; P:calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; IEA:InterPro.
DR   GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; NAS:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IDA:CAFA.
DR   GO; GO:1904637; P:cellular response to ionomycin; IEA:Ensembl.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IEA:Ensembl.
DR   GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc.
DR   GO; GO:0035397; P:helper T cell enhancement of adaptive immune response; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0035723; P:interleukin-15-mediated signaling pathway; IDA:CAFA.
DR   GO; GO:0030225; P:macrophage differentiation; IMP:ARUK-UCL.
DR   GO; GO:0032507; P:maintenance of protein location in cell; IDA:MGI.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; NAS:UniProtKB.
DR   GO; GO:0045657; P:positive regulation of monocyte differentiation; IDA:CAFA.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050863; P:regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:1904313; P:response to methamphetamine hydrochloride; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0046718; P:symbiont entry into host cell; IDA:UniProt.
DR   GO; GO:0030217; P:T cell differentiation; IDA:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProt.
DR   GO; GO:0045058; P:T cell selection; IDA:UniProtKB.
DR   CDD; cd22570; CD4_CD; 1.
DR   CDD; cd07694; IgC2_2_CD4; 1.
DR   CDD; cd07690; IgV_1_CD4; 1.
DR   CDD; cd07695; IgV_3_CD4; 1.
DR   DisProt; DP00123; -.
DR   FunFam; 1.20.5.900:FF:000001; T-cell surface glycoprotein CD4; 1.
DR   FunFam; 2.60.40.10:FF:001105; T-cell surface glycoprotein CD4; 1.
DR   FunFam; 2.60.40.10:FF:001204; T-cell surface glycoprotein CD4; 1.
DR   FunFam; 2.60.40.10:FF:001221; T-cell surface glycoprotein CD4; 1.
DR   FunFam; 2.60.40.10:FF:001253; T-cell surface glycoprotein CD4; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 4.
DR   Gene3D; 1.20.5.900; transmembrane domain of human cd4; 1.
DR   InterPro; IPR000973; CD4.
DR   InterPro; IPR015274; CD4-extracel.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR008424; Ig_C2-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR013151; Immunoglobulin_dom.
DR   InterPro; IPR021963; Tcell_CD4_Cterm.
DR   PANTHER; PTHR11422; T-CELL SURFACE GLYCOPROTEIN CD4; 1.
DR   PANTHER; PTHR11422:SF0; T-CELL SURFACE GLYCOPROTEIN CD4; 1.
DR   Pfam; PF05790; C2-set; 2.
DR   Pfam; PF09191; CD4-extracel; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF12104; Tcell_CD4_C; 1.
DR   PRINTS; PR00692; CD4TCANTIGEN.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00406; IGv; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 4.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Immunity; Immunoglobulin domain; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Proteomics identification; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000269|PubMed:15340161,
FT                   ECO:0000269|PubMed:2592374"
FT   CHAIN           26..458
FT                   /note="T-cell surface glycoprotein CD4"
FT                   /id="PRO_0000014621"
FT   TOPO_DOM        26..396
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        397..418
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        419..458
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..125
FT                   /note="Ig-like V-type"
FT   DOMAIN          126..203
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          204..317
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          318..374
FT                   /note="Ig-like C2-type 3"
FT   REGION          427..455
FT                   /note="HIV-1 Vpu-susceptibility domain"
FT   MOD_RES         433
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:2105883"
FT   MOD_RES         440
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:2105883"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:2105883"
FT   LIPID           419
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:1618861"
FT   LIPID           422
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:1618861"
FT   CARBOHYD        296
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:2001369, ECO:0000269|PubMed:2592374"
FT                   /id="CAR_000053"
FT   CARBOHYD        325
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:2001369,
FT                   ECO:0000269|PubMed:2592374"
FT                   /id="CAR_000054"
FT   DISULFID        41..109
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:2592374"
FT   DISULFID        155..184
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:2592374"
FT   DISULFID        328..370
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:2592374"
FT   VARIANT         191
FT                   /note="K -> E (in dbSNP:rs28917504)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_023459"
FT   VARIANT         227
FT                   /note="F -> S (in dbSNP:rs11064419)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_023460"
FT   VARIANT         265
FT                   /note="R -> W (in OKT4-negative populations;
FT                   dbSNP:rs28919570)"
FT                   /evidence="ECO:0000269|PubMed:1708753,
FT                   ECO:0000269|PubMed:1961196, ECO:0000269|Ref.8"
FT                   /id="VAR_003906"
FT   MUTAGEN         65
FT                   /note="Q->Y: Increases the affinity for MHCII; when
FT                   associated with W-70; R-85 and R-88."
FT                   /evidence="ECO:0000269|PubMed:21900604"
FT   MUTAGEN         68
FT                   /note="F->I: Abrogates the interaction with MHCII and T
FT                   cell activation."
FT                   /evidence="ECO:0000269|PubMed:7604010"
FT   MUTAGEN         70
FT                   /note="T->W: Increases the affinity for MHCII; when
FT                   associated with Y-65; R-85 and R-88."
FT                   /evidence="ECO:0000269|PubMed:21900604"
FT   MUTAGEN         85
FT                   /note="S->R: Increases the affinity for MHCII; when
FT                   associated with Y-65; W-70 and R-88."
FT                   /evidence="ECO:0000269|PubMed:21900604"
FT   MUTAGEN         88
FT                   /note="D->R: Increases the affinity for MHCII; when
FT                   associated with Y-65; W-70 and R-85."
FT                   /evidence="ECO:0000269|PubMed:21900604"
FT   MUTAGEN         265
FT                   /note="R->A: Has no effect on the interaction with MHCII.
FT                   Impairs recognition by OKT4 antibody."
FT                   /evidence="ECO:0000269|PubMed:7604010"
FT   MUTAGEN         432
FT                   /note="M->T: No effect."
FT                   /evidence="ECO:0000269|PubMed:8124721"
FT   MUTAGEN         433
FT                   /note="S->A: About 75% loss of internalization."
FT                   /evidence="ECO:0000269|PubMed:2105883"
FT   MUTAGEN         433
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:8124721"
FT   MUTAGEN         438..439
FT                   /note="LL->AA: Loss of Nef-induced CD4 down-modulation."
FT                   /evidence="ECO:0000269|PubMed:8124721"
FT   MUTAGEN         440
FT                   /note="S->L: No effect."
FT                   /evidence="ECO:0000269|PubMed:8124721"
FT   MUTAGEN         445
FT                   /note="C->A: Loss of homodimerization; when associated with
FT                   A-447."
FT                   /evidence="ECO:0000269|PubMed:9168119"
FT   MUTAGEN         447
FT                   /note="C->A: Loss of homodimerization; when associated with
FT                   A-445."
FT                   /evidence="ECO:0000269|PubMed:9168119"
FT   MUTAGEN         457..458
FT                   /note="Missing: Abolished interaction with SPG21 and
FT                   induced T-cell activation."
FT                   /evidence="ECO:0000269|PubMed:11113139"
FT   STRAND          27..32
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          37..39
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          51..55
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          56..58
FT                   /evidence="ECO:0007829|PDB:3LQA"
FT   STRAND          60..63
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          68..71
FT                   /evidence="ECO:0007829|PDB:4H8W"
FT   TURN            75..79
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   HELIX           84..89
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          94..96
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          105..111
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          114..128
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          131..134
FT                   /evidence="ECO:0007829|PDB:2NY1"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:1G9N"
FT   STRAND          139..144
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          158..160
FT                   /evidence="ECO:0007829|PDB:1CDJ"
FT   STRAND          162..172
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          180..188
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          191..199
FT                   /evidence="ECO:0007829|PDB:8W90"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:1CDH"
FT   HELIX           398..421
FT                   /evidence="ECO:0007829|PDB:2KLU"
FT   STRAND          426..428
FT                   /evidence="ECO:0007829|PDB:2KLU"
FT   HELIX           432..438
FT                   /evidence="ECO:0007829|PDB:3B71"
FT   STRAND          440..442
FT                   /evidence="ECO:0007829|PDB:1WBR"
SQ   SEQUENCE   458 AA;  51111 MW;  20ED893F9E56D236 CRC64;
     MNRGVPFRHL LLVLQLALLP AATQGKKVVL GKKGDTVELT CTASQKKSIQ FHWKNSNQIK
     ILGNQGSFLT KGPSKLNDRA DSRRSLWDQG NFPLIIKNLK IEDSDTYICE VEDQKEEVQL
     LVFGLTANSD THLLQGQSLT LTLESPPGSS PSVQCRSPRG KNIQGGKTLS VSQLELQDSG
     TWTCTVLQNQ KKVEFKIDIV VLAFQKASSI VYKKEGEQVE FSFPLAFTVE KLTGSGELWW
     QAERASSSKS WITFDLKNKE VSVKRVTQDP KLQMGKKLPL HLTLPQALPQ YAGSGNLTLA
     LEAKTGKLHQ EVNLVVMRAT QLQKNLTCEV WGPTSPKLML SLKLENKEAK VSKREKAVWV
     LNPEAGMWQC LLSDSGQVLL ESNIKVLPTW STPVQPMALI VLGGVAGLLL FIGLGIFFCV
     RCRHRRRQAE RMSQIKRLLS EKKTCQCPHR FQKTCSPI
//
